Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
EyePoint phase 3 for AMD disappoints, tanking stock
EyePoint turned to an ad hoc analysis in an effort to salvage the tyrosine kinase inhibitor’s performance in a phase 3 trial.
Donavyn Coffey
Aug 17, 2026 3:30pm
How AI, Creativity and Commercialization Are Converging
Brought to you by
EVERSANA INTOUCH
Quanovate scratches marketing claims for Mira fertility wand
Aug 17, 2026 2:50pm
Sanofi cuts 229 Blueprint jobs, closes Cambridge sites
Aug 17, 2026 2:41pm
AstraZeneca dual lung cancer wins softened by bispecific fail
Aug 17, 2026 10:56am
Argenx preps next potential Vyvgart nod after ph. 3 win
Aug 17, 2026 10:52am
More News
Sandoz, Henlius agree to $322M deal for 3 biosimilars
Aug 17, 2026 10:46am
Appeals court resurrects Celgene investor lawsuit against BMS
Aug 14, 2026 11:33am
EU regulators offer post-mortem of Tavneos withdrawal decision
Aug 14, 2026 11:04am
The Oral GLP-1 Tracker: Wegovy pill hits market share ceiling
Aug 14, 2026 10:41am
